63 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
Underwriters shall be entitled to receive such reimbursement.
13. Research Analyst Independence. The Company acknowledges that the Underwriters’ research
S-8
SLNO
Soleno Therapeutics Inc
31 Jan 24
Registration of securities for employees
4:19pm
for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.
See also the undertakings set out in response to Item 9
S-8
az0mv58
17 Jan 24
Registration of securities for employees
4:06pm
8-K
EX-1.1
ewy1z37h1
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
w456s ae9wecvxx
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.2
yhqx1rtf
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
nr0f3nq9dzwduurct
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
4uciijfeftgm0htc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
S-8
n5q684
8 Aug 23
Registration of securities for employees
5:25pm
8-K
EX-10.1
mowve4oqf03v
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
S-8
gyn4y485db5lwa1ajqxl
31 Mar 22
Registration of securities for employees
5:17pm
424B5
q9og0py
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
6l0j4o ioqawwfsta5
28 Mar 22
Prospectus supplement for primary offering
4:53pm